Novo Nordisk Return on Tangible Equity 2010-2023 | NVO
Current and historical return on tangible equity values for Novo Nordisk (NVO) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Novo Nordisk Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2023-12-31 |
$12.15B |
$6.70B |
219.11% |
| 2023-09-30 |
$10.84B |
$5.44B |
216.60% |
| 2023-06-30 |
$9.51B |
$5.80B |
204.42% |
| 2023-03-31 |
$8.57B |
$4.23B |
200.90% |
| 2022-12-31 |
$7.86B |
$4.54B |
192.51% |
| 2022-09-30 |
$7.66B |
$4.03B |
189.37% |
| 2022-06-30 |
$7.63B |
$4.27B |
157.52% |
| 2022-03-31 |
$7.70B |
$3.50B |
137.06% |
| 2021-12-31 |
$7.60B |
$4.39B |
120.89% |
| 2021-09-30 |
$7.45B |
$7.23B |
109.12% |
| 2021-06-30 |
$7.14B |
$7.34B |
102.24% |
| 2021-03-31 |
$6.74B |
$6.18B |
94.29% |
| 2020-12-31 |
$6.46B |
$6.54B |
87.23% |
| 2020-09-30 |
$6.23B |
$7.88B |
80.83% |
| 2020-06-30 |
$6.13B |
$8.02B |
81.50% |
| 2020-03-31 |
$6.01B |
$7.17B |
82.34% |
| 2019-12-31 |
$5.84B |
$7.76B |
82.24% |
| 2019-09-30 |
$5.62B |
$7.14B |
80.92% |
| 2019-06-30 |
$5.51B |
$7.11B |
80.65% |
| 2019-03-31 |
$5.72B |
$6.40B |
83.49% |
| 2018-12-31 |
$5.91B |
$7.14B |
85.43% |
| 2018-09-30 |
$6.16B |
$6.69B |
89.36% |
| 2018-06-30 |
$6.30B |
$7.19B |
90.28% |
| 2018-03-31 |
$6.11B |
$6.64B |
88.96% |
| 2017-12-31 |
$5.79B |
$7.06B |
88.36% |
| 2017-09-30 |
$5.73B |
$7.00B |
89.87% |
| 2017-06-30 |
$5.65B |
$6.77B |
93.21% |
| 2017-03-31 |
$5.69B |
$5.38B |
96.39% |
| 2016-12-31 |
$5.64B |
$6.32B |
96.16% |
| 2016-09-30 |
$5.59B |
$5.77B |
93.95% |
| 2016-06-30 |
$5.37B |
$6.15B |
88.62% |
| 2016-03-31 |
$5.09B |
$5.20B |
86.05% |
| 2015-12-31 |
$5.19B |
$6.67B |
89.75% |
| 2015-09-30 |
$5.08B |
$6.21B |
86.81% |
| 2015-06-30 |
$4.98B |
$5.58B |
84.14% |
| 2015-03-31 |
$5.03B |
$4.66B |
82.05% |
| 2014-12-31 |
$4.72B |
$6.94B |
73.39% |
| 2014-09-30 |
$4.74B |
$6.51B |
72.60% |
| 2014-06-30 |
$4.72B |
$6.42B |
71.94% |
| 2014-03-31 |
$4.61B |
$5.86B |
71.75% |
| 2013-12-31 |
$4.49B |
$7.29B |
70.19% |
| 2013-09-30 |
$4.38B |
$6.65B |
70.04% |
| 2013-06-30 |
$4.20B |
$5.91B |
69.58% |
| 2013-03-31 |
$3.94B |
$5.71B |
67.42% |
| 2012-12-31 |
$3.70B |
$6.76B |
64.08% |
| 2012-09-30 |
$3.53B |
$5.75B |
61.18% |
| 2012-06-30 |
$3.36B |
$5.16B |
56.56% |
| 2012-03-31 |
$3.24B |
$5.45B |
50.84% |
| 2011-12-31 |
$3.16B |
$6.72B |
48.41% |
| 2011-09-30 |
$3.06B |
$6.45B |
47.56% |
| 2011-06-30 |
$2.94B |
$6.85B |
47.09% |
| 2011-03-31 |
$2.77B |
$6.10B |
46.79% |
| 2010-12-31 |
$2.62B |
$6.33B |
44.60% |
| 2010-09-30 |
$2.35B |
$5.71B |
39.74% |
| 2010-06-30 |
$2.23B |
$5.55B |
36.46% |
| 2010-03-31 |
$2.15B |
$5.91B |
34.42% |
| 2009-12-31 |
$2.03B |
$6.50B |
33.35% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$566.147B |
$33.708B |
|
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
|
